ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

10.1016/j.jhep.2008.08.010

Saved in:

Bibliographic Details
Main Authors:	Jasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K.
Other Authors:	MEDICINE
Format:	Article
Published:	2011
Subjects:	ABT-869 Angiogenesis Hepatocellular carcinoma mTOR pathway Rapamycin Tyrosine kinase inhibitor
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/26815
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-26815
record_format	dspace
spelling	sg-nus-scholar.10635-268152024-11-14T07:46:31Z ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft Jasinghe, V.J. Xie, Z. Zhou, J. Khng, J. Poon, L.-F. Senthilnathan, P. Chen, C.-S. Albert, D.H. Davidsen, S.K. MEDICINE ABT-869 Angiogenesis Hepatocellular carcinoma mTOR pathway Rapamycin Tyrosine kinase inhibitor 10.1016/j.jhep.2008.08.010 Journal of Hepatology 49 6 985-997 2011-09-27T05:15:56Z 2011-09-27T05:15:56Z 2008 Article Jasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K. (2008). ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Journal of Hepatology 49 (6) : 985-997. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2008.08.010 01688278 http://scholarbank.nus.edu.sg/handle/10635/26815 000261708600014 Scopus
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	ABT-869 Angiogenesis Hepatocellular carcinoma mTOR pathway Rapamycin Tyrosine kinase inhibitor
spellingShingle	ABT-869 Angiogenesis Hepatocellular carcinoma mTOR pathway Rapamycin Tyrosine kinase inhibitor Jasinghe, V.J. Xie, Z. Zhou, J. Khng, J. Poon, L.-F. Senthilnathan, P. Chen, C.-S. Albert, D.H. Davidsen, S.K. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
description	10.1016/j.jhep.2008.08.010
author2	MEDICINE
author_facet	MEDICINE Jasinghe, V.J. Xie, Z. Zhou, J. Khng, J. Poon, L.-F. Senthilnathan, P. Chen, C.-S. Albert, D.H. Davidsen, S.K.
format	Article
author	Jasinghe, V.J. Xie, Z. Zhou, J. Khng, J. Poon, L.-F. Senthilnathan, P. Chen, C.-S. Albert, D.H. Davidsen, S.K.
author_sort	Jasinghe, V.J.
title	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
title_short	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
title_full	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
title_fullStr	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
title_full_unstemmed	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
title_sort	abt-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
publishDate	2011
url	http://scholarbank.nus.edu.sg/handle/10635/26815
_version_	1821183123942014976

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

Similar Items